• DAPI (hydrochloride) for Organoid DNA Analysis

  2026-08-10

  Use DAPI (hydrochloride) to connect intestinal organoid growth-state experiments with measurable nuclear DNA content, cell-cycle profiles, and chromosome-level imaging. This practical guide separates validated product characteristics from optimization starting points for fixed-cell microscopy, live-cell labeling, and flow cytometry.

• Pemetrexed A4390: Reliable Cell Assays

  2026-08-09

  This scenario-based guide shows how Pemetrexed (SKU A4390) can improve experimental planning for viability, proliferation, and cytotoxicity studies. It connects formulation, concentration selection, mesothelioma biology, and vendor evaluation to practical, evidence-based assay decisions.

• Cyclic Pifithrin-α hydrobromide: p53 Workflows

  2026-08-08

  Cyclic Pifithrin-α hydrobromide is a practical p53 inhibitor for separating p53-dependent apoptosis, growth arrest, and DNA-damage responses from p53-independent effects. This guide combines formulation guidance, controlled cell-based workflows, and a cautious extension into neuroinflammation research inspired by the CGRP/SP-Piezo2 findings in trigeminal neuralgia.

• Acetylcysteine for Redox-Aware Cancer Assays

  2026-08-07

  Acetylcysteine, also known as N-acetyl-L-cysteine, can do more than lower oxidative signals: it can help researchers distinguish redox-dependent biology from photothermal and immune effects. This article translates a metastatic TNBC nanoplatform study into practical assay-design principles for controlled, interpretable experiments.

• Cimetidine in Translational Research: Protocols & Troublesho

  2026-08-07

  Cimetidine’s distinctive partial agonist profile empowers advanced workflows in cancer and blood-brain barrier research. This guide delivers actionable protocol parameters, troubleshooting insights, and data-driven recommendations for leveraging Cimetidine’s unique pharmacological properties in high-impact experimental designs.

• Autopalmitoylation Regulates IDH1-R132H Activity in Cancer C

  2026-08-06

  This study uncovers that the oncogenic IDH1-R132H mutation is uniquely autopalmitoylated at cysteine 269, a modification that enhances its neomorphic enzyme activity in cancer. These findings reveal a mechanistic link between fatty acid metabolism and IDH1-mutant tumorigenesis, highlighting a new druggable vulnerability for targeted therapies.

• 11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch and NK

  2026-08-06

  A recent study demonstrates that selective inhibition of 11β-HSD1 attenuates liver fibrosis in a chronic mouse model by suppressing the Notch signaling pathway and enhancing NK cell-mediated clearance of hepatic stellate cells. These findings reveal a dual immunometabolic mechanism and represent a significant step forward in the development of targeted therapies for metabolic dysfunction-associated steatotic liver disease (MASLD).

• SM-102: Molecular Design and Predictive Innovation in mRNA D

  2026-08-05

  Explore the role of SM-102 in mRNA delivery systems, with a deep dive into its molecular design and machine learning-driven optimization. This article uniquely analyzes predictive innovations and practical implications for advanced mRNA vaccine development.

• Fasudil (HA-1077) HCl: Expanding Horizons in ROCK Pathway Re

  2026-08-05

  This thought-leadership article explores how Fasudil (HA-1077) HCl, a potent and selective ROCK inhibitor, enables translational researchers to dissect the mechanistic underpinnings of Rho/ROCK pathway inhibition across oncology, hematology, and emerging cross-pathway domains. By integrating rigorous mechanistic insight, protocol guidance, and contextual evidence—including recent discoveries linking Hippo and Rho/ROCK pathways—this piece charts new directions for cell signaling research and strategic experimental design.

• Coumestrol Induces Ferroptosis in RA Synoviocytes via PMAIP1

  2026-08-04

  This study demonstrates that Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 through inhibition of TRIM3-mediated ubiquitination. These findings highlight a novel mitochondrial pathway for targeting pathogenic FLS in RA and suggest new directions for therapeutic intervention.

• Autopalmitoylation of IDH1-R132H Modulates Oncogenic Activit

  2026-08-04

  This study uncovers that the oncogenic IDH1-R132H mutation undergoes unique autopalmitoylation at cysteine 269, directly enhancing its neomorphic catalytic activity in cancer cells. These findings establish a mechanistic bridge between fatty acid metabolism and IDH1-driven tumorigenesis, suggesting new avenues for therapeutic intervention and experimental study of mutant enzyme regulation.

• MCL-1’s Canonical Anti-Apoptotic Role in Breast Cancer Revea

  2026-08-03

  This study clarifies that breast cancer’s dependence on MCL-1 is driven by its canonical anti-apoptotic function, with tumor regression upon MCL-1 inhibition requiring intact BAX/BAK-mediated apoptosis. These findings sharpen therapeutic strategies targeting the mitochondrial apoptosis pathway in solid tumors.

• Targeting GOT1 in PDAC: Ziprasidone's Role in Metabolic Repr

  2026-08-03

  This article examines recent evidence that ziprasidone, a known small molecule, inhibits glutamate-oxaloacetate transaminase 1 (GOT1) and disrupts glutamine metabolism in pancreatic ductal adenocarcinoma (PDAC). These findings highlight GOT1 as a tractable metabolic target in PDAC and demonstrate the value of metabolic intervention for suppressing tumor proliferation.

• EDI3 Inhibition Targets Therapy-Resistant ER-HER2+ Breast Ca

  2026-08-02

  Keller et al. reveal that glycerophosphodiesterase EDI3 is highly expressed in ER-HER2+ breast cancer cells with resistance to HER2-targeted therapy. Their work demonstrates that silencing or inhibiting EDI3 significantly reduces cell viability and tumor growth, indicating EDI3 as a promising therapeutic target for overcoming resistance.

• Y-27632: Optimizing ROCK Inhibitor Workflows in Cell Biology

  2026-08-01

  Y-27632 enables precise, reversible modulation of cytoskeletal dynamics and ROCK signaling with unmatched selectivity. Discover practical workflows, troubleshooting tips, and the latest stem cell research advances leveraging this benchmark inhibitor from APExBIO.

8695 records 3/580 page Previous Next 12345 下5页 Last page